Document Type
Article
Publication Title
Journal of Immunotherapy and Precision Oncology
Abstract
4-1BB is a transmembrane glycoprotein found on T lymphocytes, and signaling through 4-1BB activates and differentiates CD3+ and CD8+ T cells. The ability of 4-1BB to stimulate cytotoxic T-cell responses makes it a promising target for therapeutic cancer immunotherapy development. 4-1BB antibodies have shown promising antitumor activity in preclinical studies and clinical trials. Common side effects include transaminase elevation, cytopenias, fatigue, and nausea. This clinical review summarizes past and current 4-1BB antibodies in oncology clinical trials.
DOI
10.36401/JIPO-24-30
Publication Date
3-27-2025
Keywords
4-1BB, CD137, clinical trial, immunotherapy
ISSN
2590-017X
Recommended Citation
Schwartz R, Vajrala KP, Falchook GS. 4-1BB Antibodies in Oncology Clinical Trials: A Review. Journal of Immunotherapy and Precision Oncology. 2025; 8(2). doi: 10.36401/JIPO-24-30.
